Payment overview · 2025
General Payments
$4,599.39
51 reported records · 16 companies
Healthcare provider profile · identity verified
Christopher M Bailey, DO
Allopathic & Osteopathic Physicians|Family Medicine · PRESTONSBURG, KY · NPI 1275602070
Verified facts
What the public records show
CMS Open Payments records show Christopher M Bailey, DO received $4,599.39 in general payments during 2025 across 51 reported records.
Indivior Inc. accounted for 82.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $3,787.60 | 82.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $371.62 | 8.1% | 19 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $107.34 | 2.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.70 | 1.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $38.77 | 0.8% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $36.85 | 0.8% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.57 | 0.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.08 | 0.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.33 | 0.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.95 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.58 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.20 | 0.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.09 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.51 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.94 | 0.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.26 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,637.50 | 3 |
| Food and Beverage | $961.89 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $3,737.36 | 9 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $245.80 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.05 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.05 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 502 | 86 |
| Montelukast Sodium | Montelukast Sodium | 490 | 91 |
| Omeprazole | Omeprazole | 417 | 80 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 409 | 82 |
| Lisinopril | Lisinopril | 409 | 77 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 404 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 74 |
| Losartan Potassium | Losartan Potassium | 345 | 67 |
| Furosemide | Furosemide | 321 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 81 |
| Trazodone Hcl | Trazodone Hcl | 248 | 53 |
| Potassium Chloride | Potassium Chloride | 236 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 202 | 26 |
| Metformin Hcl | Metformin Hcl | 199 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 188 | 33 |
| Ibuprofen | Ibuprofen | 183 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 41 |
| Carvedilol | Carvedilol | 171 | 33 |
| Gabapentin | Gabapentin | 169 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 157 | 36 |
| Eliquis | Apixaban | 155 | 32 |
| Alprazolam | Alprazolam | 140 | 15 |
| Irbesartan | Irbesartan | 136 | 20 |
| Sertraline Hcl | Sertraline Hcl | 136 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 30 |
| Buspirone Hcl | Buspirone Hcl | 131 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 26 |
| Famotidine | Famotidine | 130 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 13 |
| Trulicity | Dulaglutide | 124 | 19 |
| Ezetimibe | Ezetimibe | 120 | 24 |
| Simvastatin | Simvastatin | 115 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 26 |
| Lovastatin | Lovastatin | 107 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 19 |
| Meloxicam | Meloxicam | 101 | 20 |
| Linzess | Linaclotide | 100 | 21 |
| Mirtazapine | Mirtazapine | 96 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 19 |
| Mounjaro | Tirzepatide | 90 | 15 |
| Azithromycin | Azithromycin | 89 | 66 |
| Sucralfate | Sucralfate | 89 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 14 |
| Spironolactone | Spironolactone | 88 | 21 |
| Glyburide | Glyburide | 87 | 18 |
| Finasteride | Finasteride | 85 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 18 |
| Donepezil Hcl | Donepezil Hcl | 72 | 15 |
| Methylprednisolone | Methylprednisolone | 72 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 12 |
| Januvia | Sitagliptin Phosphate | 69 | 13 |
| Fluconazole | Fluconazole | 68 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | 11 |
| Gemfibrozil | Gemfibrozil | 63 | 16 |
| Nystatin | Nystatin | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Diazepam | Diazepam | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | 13 |
| Tramadol Hcl | Tramadol Hcl | 57 | 11 |
| Amoxicillin | Amoxicillin | 56 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Naproxen | Naproxen | 54 | 12 |
| Allopurinol | Allopurinol | 53 | suppressed |
| Lorazepam | Lorazepam | 53 | suppressed |
| Ozempic | Semaglutide | 53 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Valsartan | Valsartan | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 29 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Np Thyroid | Thyroid,pork | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,599.39 · 51 records | Indivior Inc. | ARISTADA, Auvelity, BRIXADI, CAPLYTA, CAPVAXIVE, COBENFY, Epclusa, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, IBSRELA, LYBALVI, MAVYRET, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, VRAYLAR, VYNDAMAX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error